complement pathway

Pathways Recommended:	MAPK/ERK Pathway

By Targets:	Complement System (15) HIV Protease (1) Liposome (1)
By Research Areas:	Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (13) Metabolic Disease (3)

Targets Recommended: Complement System

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-Y0641

3-Phenoxybenzaldehyde

m-Phenoxybenzaldehyde
Complement System Inflammation/Immunology

3-Phenoxybenzaldehyde has weak complement classical pathway inhibition and hemolytic activity .

3-Phenoxybenzaldehyde m-Phenoxybenzaldehyde	Complement System	Inflammation/Immunology
3-Phenoxybenzaldehyde has weak complement classical pathway inhibition and hemolytic activity .

HY-P99298

Lampalizumab RG 7417; TNX 234; Anti-CFD Recombinant Antibody	Complement System	Inflammation/Immunology
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .

HY-128570

FD-IN-1	Complement System	Inflammation/Immunology
FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC₅₀ of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC₅₀s of 7.7 and 6.5 µM, respectively .

HY-P99965

Crovalimab SKY59; RO7112689	Complement System	Cardiovascular Disease Metabolic Disease
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .

HY-N10104

Citrostadienol	Complement System	Inflammation/Immunology
Citrostadienol is a steroid compound with anti-inflammatory and anticomplementary activities. Citrostadienol demonstrates inhibition activities on classical **complement pathway (IC₅₀** of 46 nM) .

HY-138281

Complement factor D-IN-2	Complement System	Inflammation/Immunology
Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases .

HY-N12265

Versicolactone B	Others	Inflammation/Immunology
Versicolactone B is a sesquiterpene that can be isolated from Viola yedoensis. Versicolactone B exhibits anti-complement activity against the classical pathway and the alternative pathway .

HY-P99767

Olendalizumab ALXN1007	Complement System	Infection
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (K_i=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .

HY-117930

Danicopan 3 Publications Verification ACH-4471	Complement System	Inflammation/Immunology
Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with K_d value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .

HY-P1036

Compstatin 1 Publications Verification	Complement System	Others
Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P1036A

Compstatin TFA 1 Publications Verification	Complement System	Others
Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-122700

Factor D inhibitor 6	Complement System	Inflammation/Immunology
Factor D inhibitor 6 is a potent, highly selective and orally active factor D (FD) inhibitor with an IC₅₀ of 30 nM and a K_d of 6 nM. Factor D inhibitor 6 is inactive against factor B, lassical and lectin complement-pathway activation, and a broad assay panel of receptors, ion channels, kinases and proteases .

HY-147297

Pelecopan BCX9930	Complement System	Inflammation/Immunology
Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC₅₀ value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases .

HY-N2996

Ganodermanondiol	HIV Protease	Infection
Ganodermanondiol is a melanogenesis inhibitor isolated from the Ganoderma lucidum .Ganodermanondiol exhibits potent cytoprotective effects on tert-butyl hydroperoxide-induced hepatotoxicity . Ganodermanondiol shows significant anti-HIV-1 protease activity with an IC₅₀ of 90 μM . Ganodermanondiol exhibits a strong anticomplement activity against the classical pathway of the complement system with an IC₅₀ of 41.7μM .

HY-P990091

Riliprubart SAR 445088	Complement System	Inflammation/Immunology
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .

HY-127105

Iptacopan 3 Publications Verification LNP023	Complement System	Metabolic Disease Inflammation/Immunology
Iptacopan (LNP023) is a first-in-class, orally bioavailable, highly potent and highly selective factor B inhibitor with an IC₅₀ value of 10 nM. Iptacopan shows direct, reversible, and high-affinity binding to human factor B with a K_D of 7.9 nM. Iptacopan targets the underlying cause of complement 3 glomerulopathy (C3G) .

HY-127105A

Iptacopan hydrochloride 3 Publications Verification LNP023 hydrochloride	Complement System Liposome	Metabolic Disease Inflammation/Immunology
LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a K_D of 7.9 nM. LNP023 inhibits factor B with an IC₅₀ value of 10 nM .

Cat. No.	Product Name

HY-L001P

Bioactive Compound Library Plus	22835 compounds
Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype. MCE owns a unique collection of 22835 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc. Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. All those supplementary are supplied in powder form.

Bioactive Compound Library Plus

22835 compounds

Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype.

MCE owns a unique collection of 22835 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc.

Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. All those supplementary are supplied in powder form.

Cat. No.	Product Name	Target	Research Area

HY-P1036

Compstatin 1 Publications Verification	Complement System	Others
Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P1036A

Compstatin TFA 1 Publications Verification	Complement System	Others
Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC₅₀ values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .

HY-P5528

2Abz-SLGRKIQIK(Dnp)-NH2	Peptides	Others
2Abz-SLGRKIQIK(Dnp)-NH2 is a biological active peptide. (This peptide is a second complement component (C2), the physiological substrate for the proenzyme Cls, first complement component. The complement system is a central component of host defense but can also contribute to the inflammation seen in pathological conditions. The C1s protease of the C1 complex initiates the host defense pathway. This peptide employs 2Abz/Dnp FRET pair for quantitation of complement enzyme activity.)

Cat. No.	Product Name	Target	Research Area

HY-P99298

Lampalizumab RG 7417; TNX 234; Anti-CFD Recombinant Antibody	Complement System	Inflammation/Immunology
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .

HY-P99965

Crovalimab SKY59; RO7112689	Complement System	Cardiovascular Disease Metabolic Disease
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .

HY-P990025

Empasiprubart ARGX-117	Inhibitory Antibodies	Inflammation/Immunology
Empasiprubart (ARGX-117) a humanized inhibitory monoclonal antibody against complement C2. Empasiprubart prevents the formation of the C3 proconvertase and inhibits classical and lectin pathway activation upstream of C3 activation through binding to the Sushi-2 domain of C2. Empasiprubart exhibits pH- and calcium-dependent target binding. Empasiprubart prevents complement-mediated cytotoxicity in in vitro models for autoimmune hemolytic anemia and antibody-mediated rejection of organ transplants .

HY-P990091

Riliprubart SAR 445088	Complement System	Inflammation/Immunology
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .

HY-P99767

Olendalizumab ALXN1007	Complement System	Infection
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (K_i=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10104

Citrostadienol	Triterpenes Structural Classification Terpenoids Source classification Plants Schisandraceae Schisandra chinensis (Turcz.) Baill.	Complement System
Citrostadienol is a steroid compound with anti-inflammatory and anticomplementary activities. Citrostadienol demonstrates inhibition activities on classical **complement pathway (IC₅₀** of 46 nM) .

HY-N12265

Versicolactone B	Structural Classification Human Gut Microbiota Metabolites Viola philippica Cav. Microorganisms Terpenoids Sesquiterpenes Source classification Violaceae Plants Endogenous metabolite	Others
Versicolactone B is a sesquiterpene that can be isolated from Viola yedoensis. Versicolactone B exhibits anti-complement activity against the classical pathway and the alternative pathway .

HY-N2996

Ganodermanondiol	Infection Triterpenes Structural Classification Microorganisms Classification of Application Fields Terpenoids Polyporaceae Source classification Plants Disease Research Fields	HIV Protease
Ganodermanondiol is a melanogenesis inhibitor isolated from the Ganoderma lucidum .Ganodermanondiol exhibits potent cytoprotective effects on tert-butyl hydroperoxide-induced hepatotoxicity . Ganodermanondiol shows significant anti-HIV-1 protease activity with an IC₅₀ of 90 μM . Ganodermanondiol exhibits a strong anticomplement activity against the classical pathway of the complement system with an IC₅₀ of 41.7μM .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products